Clinical trials to maintain TFR in addition to TKI
| TIGER nilotinib ± peg-IFNA2b (phase 3) | NCT01657604 |
| PETALs nilotinib ± peg-IFNα2a (phase 3) | NCT02201459 |
| IFNA maintenance therapy | |
| TIGER peg-IFNA2b (phase 3) | NCT01657604 |
| ENDURE pegylated-proline-IFNA2b (phase 3) | NCT03117816 |
| Checkpoint inhibitors | |
| ACTIW pioglitazone (phase 1), avelumab (phase 2) | NCT02767063 |
| Dasatinib nivolumab (phase 1B) | NCT02011945 |
| JAK inhibition | |
| Preclinical data | |
| Nilotinib + ruxolitinib phase 1/2 | NCT01914484 |
| Nilotinib + ruxolitinib phase 1 | NCT02253277 |
| Nilotinib + ruxolitinib phase 1 | NCT01702064 |
| ABL-TKI + ruxolitinib phase 2 | NCT03610971 |
| ABL-TKI + ruxolitinib phase 2 | NCT03654768 |
| BCL-2 inhibition | |
| Preclinical data | |
| Dasatinib ± venetoclax phase 3 | NCT02689440 |
| BTK inhibition | |
| Preclinical data | |
| TIGER nilotinib ± peg-IFNA2b (phase 3) | NCT01657604 |
| PETALs nilotinib ± peg-IFNα2a (phase 3) | NCT02201459 |
| IFNA maintenance therapy | |
| TIGER peg-IFNA2b (phase 3) | NCT01657604 |
| ENDURE pegylated-proline-IFNA2b (phase 3) | NCT03117816 |
| Checkpoint inhibitors | |
| ACTIW pioglitazone (phase 1), avelumab (phase 2) | NCT02767063 |
| Dasatinib nivolumab (phase 1B) | NCT02011945 |
| JAK inhibition | |
| Preclinical data | |
| Nilotinib + ruxolitinib phase 1/2 | NCT01914484 |
| Nilotinib + ruxolitinib phase 1 | NCT02253277 |
| Nilotinib + ruxolitinib phase 1 | NCT01702064 |
| ABL-TKI + ruxolitinib phase 2 | NCT03610971 |
| ABL-TKI + ruxolitinib phase 2 | NCT03654768 |
| BCL-2 inhibition | |
| Preclinical data | |
| Dasatinib ± venetoclax phase 3 | NCT02689440 |
| BTK inhibition | |
| Preclinical data | |